ArticlePharmaceuticals (Basel, Switzerland)2022
Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Vismodegib-loaded ufasomes inhaler for treatment of non-small cell lung cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Liposomes-enabled gemcitabine therapy for breast cancer: in vitro and in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Control of cardiotoxicity via nasal in-situ pH-sensitive transbilosomal formulation of candesartan.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Improving the efficacy and targeting of letrozole for the control of breast cancer: in vitro and in vivo studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells.Frontiers in medical technology · 2026Article
- Formulation and Evaluation of Astaxanthin-Loaded Invasomes as Therapeutic Approaches for Alzheimer's Disease Induced in Rats: Role of SIRT-1/BDNF/miRNA-134/GSK-3β Signaling.Molecular neurobiology · 2025Article
- In Vitro and in vivo characterization of nasal pH-Responsive in-situ hydrogel of Candesartan-loaded invasomes as a potential stroke treatment.Drug delivery and translational research · 2025Article
- Liposomal Nanocarriers to Enhance Skin Delivery of Chemotherapeutics in Cancer Therapy.Bioengineering (Basel, Switzerland) · 2025Review
- Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib-Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Fabrication of an In Situ pH-Responsive Raloxifene-Loaded Invasome Hydrogel for Breast Cancer Management: In Vitro and In Vivo Evaluation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Functional candesartan loaded lipid nanoparticles for the control of diabetes-associated stroke: In vitroInternational journal of pharmaceutics: X · 2024Article
- Review
- Design, optimization, and in vivo evaluation of invasome-mediated candesartan for the control of diabetes-associated atherosclerosis.Drug delivery and translational research · 2024Article
- Krill oil: nutraceutical potential in skin health and disease.Frontiers in nutrition · 2024Review
- Formulation and Therapeutic Evaluation of Isoxsuprine-Loaded Nanoparticles against Diabetes-Associated Stroke.Pharmaceutics · 2023Article
- New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective.ACS omega · 2023Review
- New opportunities for RGD-engineered metal nanoparticles in cancer.Molecular cancer · 2023Review
- Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Skin cancer is the most frequent cancer throughout the world. Vismodegib (VSD) is a hedgehog blocker approved for the prevention and treatment of skin cancer. VSD, however, is poorly bioavailable and has been linked to side effects. This work focused on designing a nano-invasome gel as a vehicle for enhancing the permeation, bioavailability, and efficacy of VSD. Additionally, the combined effect of terpenes and ethanol was studied on the permeation of VSD compared with liposomes. The prepared VSD-loaded invasomes (VLI) formulation included cineole (1%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.